The Business Bytes
Bengaluru, December 2, 2024 (TBB Bureau): Strand Life Sciences, a subsidiary of Reliance Industries Limited, has unveiled CancerSpot, a revolutionary blood-based test for the early detection of multiple cancers. The test leverages cutting-edge methylation profiling technology to identify tumor DNA fragments in the bloodstream, providing a breakthrough in proactive cancer screening.
CancerSpot requires only a simple blood sample, offering a hassle-free, non-invasive alternative for early cancer detection. Using proprietary genome sequencing and analysis, the test identifies DNA methylation signatures unique to cancer. Developed with data from Indian cohorts, these signatures have demonstrated efficacy across diverse global populations, making CancerSpot a robust tool for routine and proactive cancer screening.
At the launch event, Isha Ambani Piramal, Member of the Board at Reliance Industries, emphasized the significance of this innovation. “Cancer is a leading cause of morbidity and mortality in India, imposing a heavy burden on patients, families, and communities. Strand’s pioneering cancer detection test exemplifies Reliance’s commitment to transformative healthcare solutions. With CancerSpot, we aim to improve lives in India and beyond, reflecting our ‘WE CARE’ corporate philosophy.”
The launch coincided with the inauguration of Strand Life Sciences’ state-of-the-art Genomics Diagnostics & Research Centre in Bengaluru. Spanning 33,000 square feet, this advanced facility is equipped with cutting-edge sequencing technologies and fosters collaboration among bioinformatics experts, molecular biologists, and clinical teams.
Speaking at the inauguration, Dr. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences, stated, “Early detection is the cornerstone of effective cancer treatment. CancerSpot empowers individuals to stay ahead of cancer, offering hope for improved outcomes. This achievement is the result of years of rigorous research and innovation, solidifying Strand’s position as a leader in genomics.”
The center was inaugurated by Dr. Charles Cantor, a globally renowned genomics expert and former professor at Columbia University, UC Berkeley, and Boston University. The facility is set to drive the CancerSpot program, accelerate groundbreaking research, and deliver life-saving diagnostics for both Indian and global populations.
